百奧賽圖 北京 醫藥科技股份有限公司 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (A joint stock company incorporated in the People's Republic of China with limited liability) （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） Stock code 股份代號：2315 INTERIM REPORT 中期報告 2024 目錄 CONTENTS | 2 | 公司資料 | Corporate Information | | --- | --- | --- | | 6 | 財務概要 | Financial Summary | | 7 | 管理層討論與分析 | Management Discussion and Analysis | | 59 | 企業管治及其他資料 | Corporate Governance and Other Information | | 84 | 審閱報告 | Review Report | | 86 | 綜合損益及其他 ...

模型以及药理药效这一部分在过去几年里面一直在稳定持续的增长第二部分是我们的抗体分子也就是我们的千树万炕业务这是基于我们白赛图基因技术开发的全能抗体属于麦思系列产生了将近上千个把柄的抗体分子也就是我们的千树万炕白赛图是一家只根据中国成为全球性的一个生物技术公司 我们在北京、江苏海门、美国的波士顿、旧金山以及德国的海德堡都有我们的生态研发中心以及商务中心可以看到这是白赛土的一个业务逻辑白赛土有一个世界一流的基因编辑技术团队大概有150人的团队 我们在过去的十年的时间里面除了对客户进行基因编辑的精确小鼠的智慧服务以外大部分的时间大部分的精力是开发自主创新的动物模型尤其是由于药物研发的八点人变化老鼠模型这些小鼠出售给我们带来大量的收入同时利用我们自主创新的动物模型进行药理药效服务也就是为客户进行药物药效临床前的药效评价 另一个优先的就是我们的全人体抗体术就是REMAPS系列这也是由我们基因编辑团队经过7个实验的时间开发出来的REMAPSREMAPS系列的REMAPS系列在2020年的时候我们完成了REMAPS系列小组以后我们在这个小组的基础上就针对上千个靶点进行抗体开发 由此我们产生了大概40万个抗体分子这些抗体分子 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. 百奧賽圖（北京）醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2315） 截至2024年6月30日止六個月的中期業績公告 百奧賽圖（北京）醫藥科技股份有限公司（「本公司」或「百奧賽圖」）董事（「董事」） 會（「董事會」）欣然宣佈本公司及其附屬公司（統稱「本集團」）截至2024年6月30日 止六個月（「報告期間」）的未經審核綜合業績，連同2023年同期的比較數字。 財務摘要 | --- | --- | --- | --- | |-------------------------------|--------------|--------------|----------| | | 截至 | 截至 | | | | 2024 年 | 2023 年 | | | | 6 月 30 日 | ...

(3) 百奥赛图 百奥賽圖 (北京)醫藥科技股份有限公司 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (A joint stock company incorporated in the People's Republic of China with limited liability) (於中華人民共和國註冊成立的股份有限公司) Stock code 股份代號：2315 Annual Report IIIII II HIII II IIII EF l Flin | --- | --- | --- | --- | --- | --- | --- | |-------|-------|-----------------------------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | IIIIIIII IIIIII IIIIII IIII | | | | | | | | HI HIDDI HOUDIN ...

研究报告Research Report 3 Apr 2024 百奥赛图 Biocytogen Pharmaceuticals (2315 HK) 2023 年点评：海外收入快速增长，千鼠万抗完成阶段性研发，自研管线对外授权转让顺利 23FY Review: Overseas Revenue has Grown Rapidly, Phased Research and Development has Been Completed, and Clinical Pipelines License out [观Ta点bl聚e_焦yem Inevie1s] tment Focus [Tab 维le_ 持Inf 优o] 于大市Maintain OUTPERFORM (Please see APPENDIX 1 for English summary) 事件 评级 优于大市OUTPERFORM 现价 HK$8.20 公司发布 2023 年业绩：2023 年，营业收入 7.17 亿元（+34%）， 目标价 HK$16.25 海外营收4.08亿元（+66%），毛利率为70.6%（+2.8pp），净利润 亏损 3.83 亿元（2 ...

Revenue Growth - Revenue increased by 34.3% to RMB 716.9 million in 2023 compared to RMB 533.9 million in 2022[2] - Revenue from gene editing services increased to RMB 74,325 thousand in 2023, up from RMB 61,075 thousand in 2022, representing a growth of 21.7%[13] - Revenue from preclinical pharmacology and efficacy evaluation services rose to RMB 193,396 thousand in 2023, compared to RMB 176,069 thousand in 2022, a 9.8% increase[13] - Model animal sales revenue surged to RMB 272,805 thousand in 2023, a significant 61.1% increase from RMB 169,328 thousand in 2022[13] - Antibody development revenue grew to RMB 175,870 thousand in 2023, up from RMB 126,887 thousand in 2022, marking a 38.6% increase[13] - Total revenue from customer contracts reached RMB 716,912 thousand in 2023, a 34.3% increase from RMB 533,881 thousand in 2022[13] - Revenue from the United States increased to RMB 301,169 thousand in 2023, up from RMB 178,993 thousand in 2022, a 68.3% growth[24] - Revenue from China grew to RMB 308,610 thousand in 2023, compared to RMB 287,736 thousand in 2022, a 7.3% increase[24] - Revenue from antibody development business reached RMB 175.9 million in 2023, a 38.6% increase year-over-year, while model animal sales revenue grew by 61.1% to RMB 272.8 million[43] - Overseas revenue accounted for 57.0% of total revenue in 2023, reaching RMB 408.3 million, a 65.9% increase compared to the previous year[43] - Total revenue increased by 34.3% from RMB 533.9 million in 2022 to RMB 716.9 million in 2023, driven by growth in model animal sales and antibody development[104] - Model animal sales revenue increased to RMB 272.805 million in 2023, accounting for 38.1% of total revenue[104] - Antibody development revenue grew to RMB 175.870 million in 2023, representing 24.5% of total revenue[104] Profit and Loss - Gross profit rose by 29.2% to RMB 506.0 million in 2023 from RMB 391.8 million in 2022[2] - Pre-tax loss decreased by 36.8% to RMB 380.2 million in 2023 from RMB 601.4 million in 2022[2] - Net loss for the year reduced by 36.4% to RMB 383.0 million in 2023 from RMB 602.2 million in 2022[2] - Basic and diluted loss per share decreased by 39.2% to RMB 0.96 in 2023 from RMB 1.58 in 2022[2] - Total reportable segment gross profit for 2023 was RMB 506,351 thousand, up from RMB 392,523 thousand in 2022, a 29.0% increase[23] - The company's pre-tax loss for 2023 was RMB 380,156 thousand, compared to RMB 601,353 thousand in 2022[33] - The company's net loss narrowed by approximately 36.4% in 2023, with plans to achieve near break-even by the end of 2024 through further expansion into high-margin overseas markets and cost control[44] - Gross profit increased by 29.2% from RMB 391.8 million in 2022 to RMB 506.0 million in 2023, driven by increased revenue from model animal sales and antibody development[106] - Gross margin decreased from 73.4% in 2022 to 70.6% in 2023, primarily due to the relocation to a new laboratory in Boston, USA, which reduced the gross margin of preclinical pharmacology and antibody development[106] - The company reported a net loss of RMB 383.0 million in 2023, compared to a net loss of RMB 602.2 million in 2022[117] R&D and Innovation - R&D expenses decreased by 32.2% to RMB 474.4 million in 2023 from RMB 699.2 million in 2022[3] - R&D expenses decreased by 32.2% to RMB 474.4 million in 2023 from RMB 699.2 million in 2022, as the company concluded its large-scale R&D investment phase[43] - R&D personnel totaled 366 as of December 31, 2023, with R&D expenses of RMB 474.4 million in 2023, down from RMB 699.2 million in 2022[89] - Core product R&D expenses were RMB 65.5 million in 2023, accounting for 13.8% of total R&D expenses[89] - R&D expenses decreased by 32.2% from RMB 699.2 million in 2022 to RMB 474.4 million in 2023, mainly due to reduced employee costs, outsourcing fees, and direct material costs[112] - The company's antibody development platform, RenMice, has generated a library of 400,000 to 500,000 antibody sequences for over 1,000 targets, enabling the identification of potential therapeutic antibody molecules[44] - The company's preclinical research services, including gene editing and model animal sales, have gained recognition from both domestic and international clients, contributing to rapid revenue growth and high margins[44] - The company's strategy involves advancing a small number of promising drug molecules to the preclinical stage and then partnering with biotech and pharmaceutical companies for further development and commercialization[45] - The company has completed the development of the "Thousand Mice Ten Thousand Antibodies" project and built a large antibody sequence library by the end of Q3 2023[46] - The "Thousand Mice Ten Thousand Antibodies" project has evaluated approximately 1,000 targets and developed over 800 targets, with a library of 400,000 to 500,000 fully human antibody sequences covering more than 1,000 innovative targets[48] - The company has knocked out over 680 target genes in RenMab and over 270 target genes in RenLite as part of the "Thousand Mice Ten Thousand Antibodies" project[48] - The company plans to expand the antibody library by developing bispecific antibodies and nanobodies using RenLite and RenNano technology platforms[48] - The company's business model involves commercializing antibodies through co-development, authorized transfers, and transfer development agreements, generating revenue from upfront payments, milestone payments, and sales royalties[48] - The company's revenue currently comes mainly from upfront payments, with milestone payments and sales royalties expected to grow significantly in the future[48] - The company's gene editing technology supports antibody discovery and model animal platforms, including the RenMice platform[79] - The company's gene editing services focus on overseas pharmaceutical clients to enhance profitability and value contribution[78] - The company's gene editing platforms include SUPCE, CRISPR/EGE, and ESC/HR, driving technological innovation[80] - The company provides customized gene editing services for rats/mice and cell lines, with final products including animal or cell line models with specific genotypes, genotyping reports, and project completion reports[81] - The company's proprietary SUPCE technology enables chromosome editing on a million-base scale, with high stability and repeatability, as demonstrated by the RenMice platform[82] - The RenMice platform has been licensed to several multinational pharmaceutical companies, including Merck Healthcare KGaA, Johnson & Johnson, Xencor, BeiGene, and Innovent Biologics, generating upfront payments, milestone payments, and sales royalties[83] - The RenMab platform, which uses RenMab mice to discover and generate fully human monoclonal antibodies, has obtained patents in China and the United States in 2023[84] - The RenLite platform generates high-affinity bispecific antibodies and bispecific ADCs, with the ability to produce bispecific ADCs targeting two tumor antigens, such as YH012 and YH013[85][86] - The RenNano platform produces fully human single-chain antibody fragments without the need for in vitro humanization, enabling high-throughput development of fully human heavy-chain antibodies[87] - The RenTCRm platform, based on RenMice, generates fully human antibodies targeting intracellular antigens, providing more candidate molecules for antibody-related drugs and CAR-T therapies[88] - GPCR platform developed based on RenMice, generating highly diverse fully human antibodies with high screening success rates[89] Clinical Trials and Drug Development - YH001 achieved an objective response rate (ORR) of 19.2% (95% CI: 6.6, 39.4) and a disease control rate (DCR) of 61.5% (95% CI: 40.6, 79.8) in a Phase I trial with 26 evaluable patients[50] - YH001 is being evaluated in a Phase I/II trial in the US for advanced or metastatic sarcoma, with 176 patients expected to be enrolled[51] - YH003 demonstrated a complete response (CR) in one patient with pancreatic cancer, who maintained CR status as of June 30, 2023[52] - YH003 Phase II MRCT enrolled 92 PDAC patients, with 47 in the first-line treatment group and 45 in the second-line and beyond treatment group[52] - YH003006 study in China enrolled 20 patients for the treatment of unresectable/metastatic mucosal melanoma, with results expected in the first half of 2024[53] - YH003005 study enrolled 15 patients for the treatment of advanced solid tumors in China and Australia[54] - YH002 Phase I trial showed a disease control rate (DCR) of 20% in 15 patients with advanced solid tumors[55] - YH002 was well-tolerated at doses up to 2.0mg/kg, with 46.7% of patients experiencing treatment-related adverse events (TEAEs)[55] - YH002 reported 3 serious adverse events (SAEs) at the 3.0mg/kg dose level, with no drug-related deaths[55] - YH002 demonstrated disease stabilization (SD) in 3 out of 15 patients based on RECIST v1.1 criteria[55] - YH002 has entered clinical trials in Mexico with promising initial clinical data showing anti-tumor activity[56] - YH004 Phase I clinical trial enrolled 17 patients with doses ranging from 0.01mg/kg to 3.0mg/kg, showing good safety and tolerability[57] - YH005 (RC118) received two orphan drug designations from the FDA for gastric and pancreatic cancer treatment[58] - YH008 secured a licensing deal with Microcore New Domain, including a RMB 40 million upfront payment and up to RMB 556 million in milestone payments[60] - YH012, a HER2/TROP2 bispecific ADC, entered an exclusive option and licensing agreement with Radiance in January 2024[61] - YH013, an EGFR/MET bispecific ADC, signed an exclusive option and licensing agreement with Doma Medical in 2023[62] - YH015, a CD40-targeting antibody, is currently in the CMC stage with potential applications in autoimmune diseases and organ transplantation[63] - YH016 and YH017, novel antibodies targeting myeloid cells and T/NK cells, have identified high-affinity candidate antibodies for further development[64] - YH001 is a recombinant humanized anti-CTLA-4 IgG1 monoclonal antibody[142] - YH002 is a recombinant humanized IgG1 antibody targeting the human OX40 receptor[142] - YH003 is a recombinant humanized agonistic anti-CD40 IgG2 monoclonal antibody[142] - YH004 is a humanized IgG1 anti-4-1BB agonist[142] - YH008 is an anti-PD-1/CD40 bispecific antibody for the treatment of solid tumors[142] - YH012 and YH013 are two bispecific ADCs developed using the RenLite platform, planned for the treatment of solid tumors[142] - YH015 is a fully human IgG1 anti-CD40 monoclonal antibody[142] - YH016 and YH017 are two novel molecules developed using the RenMice platform for the treatment of solid tumors and immune diseases, respectively[143] - 4-1BB is a receptor expressed on activated T cells and NK cells, providing co-stimulatory signals to promote T cell proliferation, survival, and cytotoxic effects[143] Financial Position and Expenses - Cash and bank balances decreased by 33.4% to RMB 417.7 million in 2023 from RMB 626.6 million in 2022[4] - Total equity decreased by 31.3% to RMB 790.4 million in 2023 from RMB 1,150.8 million in 2022[7] - The remaining performance obligation under existing contracts as of December 31, 2023, was RMB 182,160 thousand, expected to be recognized over the next 3 years[14] - Other income and losses net amount for 2023 was RMB 42,259 thousand, compared to RMB 86,710 thousand in 2022[25] - Net fair value change of biological assets for 2023 included realized fair value negative change of RMB 59,940 thousand and unrealized fair value positive change of RMB 64,819 thousand[26] - Financial costs for 2023 increased to RMB 99,844 thousand from RMB 56,139 thousand in 2022, mainly due to higher interest on long-term payables[27] - Employee costs for 2023 decreased to RMB 404,065 thousand from RMB 419,895 thousand in 2022, with a notable increase in equity-settled share-based payment expenses[28] - Depreciation of property, plant, and equipment for 2023 was RMB 182,299 thousand, up from RMB 171,034 thousand in 2022[31] - The company enjoyed a preferential tax rate of 15% in 2023 due to its high-tech enterprise qualification[34] - Basic loss per share for 2023 was calculated based on a net loss attributable to ordinary shareholders of RMB 382,951 thousand[35] - Trade receivables as of December 31, 2023, amounted to RMB 142,205 thousand, up from RMB 107,682 thousand in 2022[38] - The aging analysis of trade receivables showed that 88.5% were within 1 year, 10% were 1-2 years, and 1.5% were 2-3 years as of December 31, 2023[39] - Trade payables and notes payable increased to RMB 175,234 thousand in 2023 from RMB 146,190 thousand in 2022, with a significant rise in payables to third parties from RMB 104,968 thousand to RMB 115,113 thousand[40] - The company's issued and fully paid ordinary shares increased to 399,398 thousand shares by the end of 2023, following the issuance of 24,468 thousand new shares in 2022[41] - Sales costs increased by 48.4% from RMB 142.1 million in 2022 to RMB 210.9 million in 2023, in line with revenue growth[105] - Other income and losses decreased by 51.3% from RMB 86.7 million in 2022 to RMB 42.3 million in 2023, mainly due to a decrease in fair value changes of financial assets and foreign exchange gains[107] - Sales and marketing expenses increased by 25.0% from RMB 50.2 million in 2022 to RMB 62.8 million in 2023, largely due to salary increases in line with revenue growth[110] - General and administrative expenses increased by 8.7% from RMB 263.4 million in 2022 to RMB 286.3 million in 2023, primarily due to increased depreciation, amortization, and rental expenses from the new Boston facility[111] - Cash and cash equivalents decreased from RMB 626.6 million in 2022 to RMB 417.7 million in 2023, primarily due to net operating losses[114] - Financial costs increased by 77.9% from RMB 56.1 million in 2022 to RMB 99.8 million in 2023, driven by higher interest on long-term payables and bank loans[116] - The asset-liability ratio increased from 1.43 in 2022 to 2.10 in 2023, reflecting higher liabilities relative to equity[118] - Total capital expenditure for the year ended December 31, 2023, was approximately RMB 79.8 million, primarily for facility and office building investments and scientific equipment purchases[120] - The company mortgaged its factory and buildings in Baiao Situ Daxing for long-term bank loans, with a net book value of RMB 239,542,000 as of December 31, 2023[121] - Net proceeds from the global offering amounted to approximately HKD 537.0 million (equivalent to RMB 436.3 million), with 70% allocated to core product clinical R&D[125][126] - As of December 31, 2023, the company had utilized HKD 480.5 million of the net proceeds, leaving HKD 56.5 million unused, which is expected to be fully utilized by December 31, 2024[126][127] - The company allocated 35% of the net proceeds (HKD 188.0 million) to YH003 R&D and 35% (HKD 188.0 million) to YH001 clinical development[126] - 15% of the net proceeds (HKD 80.6 million) was used for facility construction and equipment procurement under the "Thousand Mice, Ten Thousand Antibodies" program[126] - The company has no significant contingent liabilities or major investments as of December 31, 2023[120][121] - The company has not conducted any significant acquisitions or disposals of subsidiaries, associates, or joint ventures during the year[122] - The company’s audit committee reviewed and confirmed compliance with accounting standards and regulations for the financial year ended December 31, 2023[128] - The board has decided not to recommend a final dividend for the year ended December 31, 2023 (2022: none)[130] - The company will suspend share transfer registration from May 23, 2024, to May 28, 2024, to determine shareholder eligibility for the annual general meeting on May 28, 2024[130] - The annual report for the year ended December 31, 2023, will be sent to shareholders and published on the Hong Kong Stock Exchange and the company

(3) 百奥賽图 百奥賽圖(北京)醫藥科技股份有限公司 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (A joint stock company incorporated in the People's Republic of China with limited liability) (於中華人民共和國註冊成立的股份有限公司) Stock code 股份代號：2315 2023 中 期 報 告 2023 Interim Report III 1111 1111 1111 1111 11 WANTAN HITH III) HILL III III III III III III III III III HUHLANDA MINUTE III IIII III III III III min mi mi m HINDICHING HUMO HINNER HUHT WHITE See West mmm IIIIiin 电竞竞 竞彩手机 HI HI HU HU MI W III HU HUMUM WA | --- | --- | --- | --- | --- | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. 百奧賽圖（北京）醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2315） 截至2023年6月30日止六個月的中期業績公告 百奧賽圖（北京）醫藥科技股份有限公司（「本公司」或「百奧賽圖」）董事（「董事」） 會（「董事會」）欣然宣佈本公司及其附屬公司（統稱「本集團」）截至2023年6月30日 止六個月（「報告期間」）的未經審核綜合業績，連同2022年同期的比較數字。 財務摘要 | --- | --- | --- | --- | |------------------------------|--------------|--------------|----------| | | 截至 | 截至 | | | | 2023 年 | 2022 年 | | | | 6 月 30 日 | 6 ...

3 百興賽图 百奥賽圖 (北京)醫藥科技股份有限公司 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (A joint stock company incorporated in the People's Republic of China with limited liability) (於中華人民共和國註冊成立的股份有限公司) Stock code 股份代號：2315 2022 年度報告 Annual Report nton high in the HHT III III III III III ITHEMERATION IN II I HIHITO HIlliam HI IIIII III TH HIGH THE THE THE FAR unu munumum armannan 0111 111111111111111 I IIII III IIII IIII odiff []] []] []] ITHER | --- | --- | --- | --- | --- | |-------|----------------------------------- ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. 百奧賽圖（北京）醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2315） 截至2022年12月31日止年度的年度業績公告 百奧賽圖（北京）醫藥科技股份有限公司（「本公司」或「百奧賽圖」）董事（「董事」） 會（「董事會」）欣然宣佈本公司及其附屬公司（統稱「本集團」）截至2022年12月31 日止年度（「報告期」）的經審核綜合年度業績連同2021年同期的經審核比較數據。 財務摘要 | --- | --- | --- | |-------------------|---------------------|----------| | | | | | 截至 2022 年 | 截至 2021 年 | | | 12 月 31 日 | 12 月 31 日 | | | 止年度 人民幣千元 | 止 ...